Company Overview and News
Earnings season got busy this week with the remainder of the big financial firms, most of our top industrial companies, and the first wave of tech leaders announcing their latest quarterly results. This week saw solid results across the board, with impressive revenue growth punctuating continued EPS expansion.
FB TXN GOOGL
Previous articles tracked how portfolios composed of high-yield CEFs, BDCs, MLPs and mREITs "failed" by underperforming the market significantly since 2014.
RSO.PRC HD HE GIS PG HE.PRU TXN RSO.PRBCL ADP RSO.PRACL MCQ RCL HRZN HTF BAX MCV OSLE VZA UHT IP CUKPF CCL HTFA INTC TUP RSO MCC WMC GD INPAP CCL CUK WM NMFC OCSL MCX ADPVV XAN PPL RTN ADI VZ RSO.PRA RSO.PRB
Chicago, IL –July 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo (WFC - Free Report) , IBM (IBM - Free Report) , Abbott (ABT - Free Report) , Texas Instruments (TXN - Free Report) and Praxair (PX - Free Report) .
WFCNP TXN MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS MS.PRI PX MS.PRK
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFC WFCNP HD WFC.WS TXN WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP PX WFC.PRO WFC.PRN CERN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Investors focused on the Computer and Technology space have likely heard of Texas Instruments (TXN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question.
Investors focused on the Computer and Technology space have likely heard of Texas Instruments (TXN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Computer and Technology peers, we might be able to answer that question.
Taiwan Semiconductor Manufacturing Company (TSM - Free Report) delivered second-quarter 2018 earnings of 47 cents per ADR unit surpassing the Zacks Consensus Estimate by 2 cents and also improved the year-ago quarter figure of 42 cents. However, it declined from the previous quarter figure of 59 cents. Adjusted revenues grew 11.2% on a year-over-year basis but fell 7.2% sequentially to $7.85 billion.
TXN ADI AME
According to a statement from the company, Texas Instruments CEO Brian Crutcher has resigned from his roles at the company after violating its code of conduct. The company doesn’t say exactly what happened, but it notes that the former CEO’s actions are not consistent with its ethics and core values.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TXN / Texas Instruments Inc. on message board site Silicon Investor.
as of ET